News | November 17, 2010

Catheter Ablation Improves Quality of Life in AFib Patients

November 17, 2010 – Atrial fibrillation (AFib) patients treated with catheter ablation reported fewer symptoms and improved quality of life, according to data from Circulation Cardiovascular Quality and Outcomes. The patients, who were treated with Biosense Webster’s NaviStar ThermoCool catheter, were compared with patients treated with antiarrhythmia drugs.

During cardiac ablation, a catheter inserted into the heart delivers energy to those areas of the heart muscle causing the abnormal heart rhythm. The technique “disconnects” the pathway of the abnormal rhythm.

Data showed that, at one year, 66 percent of patients treated with catheter ablation remained AFib-free, compared to only 16 percent of patients treated with anti-arrhythmic drugs. Patients in the catheter ablation groups also experienced a significant improvement in quality of life. Those who were 10 to 20 percent below population norms saw their quality of life return to normal. Additionally, symptom frequency and severity scores decreased by more than 50 percent in the ablation group, but were unchanged in the drug group.

“An in-depth analysis of the trial's data revealed that, for the population studied, nine of 10 specific measures of quality of life and symptom burden – all except bodily pain – were superior in the group treated with catheter ablation, compared to the drug group,” said Matthew Reynolds, M.D., M.Sc., primary investigator for the sub-study and lead author, and medical director of the economics and quality of life assessment group at the Harvard Clinical Research Institute in Boston. “These differences persisted for the duration of the trial and were strongly associated with recurrent arrhythmias, which were much more frequent in the antiarrhythmic drug group. These results add to a growing body of literature demonstrating that catheter ablation improves quality of life more than antiarrhythmic drugs in appropriately selected patients."

AFib is the most prevalent heart rhythm disorder, yet most patients are treated with medication. In about half of them, the drugs do not control the symptoms.

“The results of this study provide important information for patients with AFib and their physicians because it demonstrates that effective treatment of AFib through an intervention like ablation can reduce the severity of their symptoms and improve the quality of their life,” Reynolds said.

The NaviStar ThermoCool is the only ablation catheter approved by the U.S. Food and Drug Administration for treating drug refractory recurrent symptomatic paroxysmal AFib

For more information: www.biosensewebster.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init